CALC
CalciMedica, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.17
−1.36%Aug 20, 2026, 00:00 UTC
CalciMedica, Inc. elected Allan Shaw and Robert N. Wilson as Class III directors, effective August 19, 2026.
Aug 11, 2026, 00:00 UTC
CalciMedica, Inc. completed a private placement raising approximately $49 million in gross proceeds, with approximately $15 million upfront.
Source:Aug 11, 2026, 00:00 UTC
CalciMedica, Inc. reported a net loss of $7.652 million for Q2 2026, with diluted EPS of -$0.45.
Source:Jul 29, 2026, 11:00 UTC
CalciMedica announced FDA alignment on Phase 2b trial design for Auxora in acute pancreatitis, including endpoints and enrichment strategy.
Source:Jun 24, 2026, 11:01 UTC
CalciMedica entered into a definitive securities purchase agreement for a private placement of up to approximately $49 million in gross proceeds to advance its pulmonary hypertension program.
Source:Jun 24, 2026, 00:00 UTC
CalciMedica, Inc. amended a warrant to purchase common stock, reducing the exercise price from $2.32 to $1.00 per share, and amended a loan conversion option for up to $3,000,000 of principal into common stock or pre-funded warrants, both on June 23, 2026.